Morgan Stanley Sees Multiple Challenges Ahead for The Clorox Co.

In a report published Wednesday, Morgan Stanley analyst Dara Mohsenian reiterated an Underweight rating and $85.00 price target on

. In the report, Morgan Stanley noted, “We remain UW [on] CLX given we believe weak US consumer spending, heightened competition with incremental promotion, and Venezuela/Argentina risk, will limit near-term results, which is not fully reflected in valuation, particularly given CLX's long-term EPS growth potential is below peers.” The Clorox Co. closed on Tuesday at $85.81.